Pulmonary Tuberculosis Chemotherapy Regimen — free guideline decision tool
This tool gives the standardized pulmonary tuberculosis chemotherapy regimen by new, retreatment, or drug-resistant status, with principles and monitoring.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Treatment category | New (susceptible) |
|---|
→Regimen2HRZE/4HR (6 months)
- Recommended regimen：2HRZE/4HR: intensive phase 2 months (isoniazid H + rifampin R + pyrazinamide Z + ethambutol E), continuation phase 4 months (HR), 6 months total
- Principles：early, combined, appropriate dose, regular, complete; single daily dose, regular and complete, with directly observed therapy (DOT) throughout; sputum at end of month 2 and 5; if still positive at month 2, extend the intensive phase by 1 month
- Monitoring：Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly
| Treatment category | Rifampin-resistant / multidrug-resistant (RR/MDR) |
|---|
→RegimenMDR regimen (specialist)
- Recommended regimen：Rifampin-resistant/multidrug-resistant (RR/MDR-TB): do not use the standard first-line regimen, build an individualized longer or shorter MDR regimen per susceptibility (including bedaquiline, linezolid, etc.), refer to a TB specialist
- Principles：early, combined, appropriate dose, regular, complete; needs TB-specialist and standardized management (DOT, adverse-event monitoring, social support)
- Monitoring：Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly
Common questions
What is Pulmonary Tuberculosis Chemotherapy Regimen?
This tool gives the standardized pulmonary tuberculosis chemotherapy regimen by new, retreatment, or drug-resistant status, with principles and monitoring.
How is Pulmonary Tuberculosis Chemotherapy Regimen calculated? What is the core formula?
New susceptible → 2HRZE/4HR (6 months) with DOT. Retreatment → susceptibility-guided (classically streptomycin-containing). RR/MDR → individualized regimen (bedaquiline, linezolid) by susceptibility, specialist-managed.
When is Pulmonary Tuberculosis Chemotherapy Regimen used?
Use to select the regimen — 2HRZE/4HR for new susceptible TB, susceptibility-guided retreatment, and an individualized MDR regimen with referral.
What are the key clinical points for Pulmonary Tuberculosis Chemotherapy Regimen?
Resistance screening before treatment is emphasized so retreatment and drug-resistant cases are never managed by blindly reusing the first-line regimen. (original synthesis · not guideline verbatim) DOT and full-course adherence underpin all regimens. Monitoring covers hepatotoxicity (H/R/Z), vision/color vision (E), and uric acid (Z).
What are the limits and cautions when using Pulmonary Tuberculosis Chemotherapy Regimen?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
How is Pulmonary Tuberculosis Chemotherapy Regimen calculated in practice? Can you show a worked example?
Inputs: Treatment category New (susceptible) → Result: Regimen 2HRZE/4HR (6 months)（Recommended regimen: 2HRZE/4HR: intensive phase 2 months (isoniazid H + rifampin R + pyrazinamide Z + ethambutol E), continuation phase 4 months (HR), 6 months total, Principles: early, combined, appropriate dose, regular, complete; single daily dose, regular and complete, with directly observed therapy (DOT) throughout; sputum at end of month 2 and 5; if still positive at month 2, extend the intensive phase by 1 month, Monitoring: Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly） Inputs: Treatment category Rifampin-resistant / multidrug-resistant (RR/MDR) → Result: Regimen MDR regimen (specialist)（Recommended regimen: Rifampin-resistant/multidrug-resistant (RR/MDR-TB): do not use the standard first-line regimen, build an individualized longer or shorter MDR regimen per susceptibility (including bedaquiline, linezolid, etc.), refer to a TB specialist, Principles: early, combined, appropriate dose, regular, complete; needs TB-specialist and standardized management (DOT, adverse-event monitoring, social support), Monitoring: Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly）
Run Pulmonary Tuberculosis Chemotherapy Regimen now
This tool gives the standardized pulmonary tuberculosis chemotherapy regimen by new, retreatment, or drug-resistant status, with principles and monitoring.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.